Bibliography
- OFFICIAL STATEMENT OF THE AMERICAN THORACIC SOCIETY: Standards for the diagnosis and care of patents with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (1995) 1 5 2:S77–S120.
- •Comprehensive review of COPD.
- SIAFAKAS NM, VERMEIRE P, PRIDE NB, et al.: A consensus statement of the European Respiratory Society. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur. Resp. (1995) 8: 1398–1420.
- •Comprehensive review of COPD.
- STANDARDS OF CARE COMMITTEE OF THE BRITISH THORACIC SOCIETY: Summary of COPD guidelines. Thorax (1997) 52 (Suppl. 5):S1–S28.
- •Comprehensive review of COPD.
- NATIONAL INSTITUTES OF HEALTH: Chronic Obstruc-tive Pulmonary Disease. NIH Publication. 95–2020.
- JEFFERY P: Structural and inflammatory changes in COPD: a comparison with asthma. Thorax (1998) 53:129–136.
- SAETTA M: Airway inflammation in chronic obstruc- tive pulmonary disease. Am. J. Respir. Crit. Care Med. (1999) 1 6 0:S17–S20.
- •Comprehensive review of inflammation in COPD.
- POSTMA DS, KERSTJENS HAM: Are inhaled glucocorti-costeroids effective in chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. (1999) 1 60 :S66–S71.
- DE BRITO FB, SOUNESS JE, WARNE PJ: Type 4phosphodiesterase inhibitors and their potential in the treatment of inflammatory disease. Emerging Drugs (1997) 2:249–268.
- STOCKLEY RA: Neutrophils and protease/antiproteaseimbalance. Am. J. Respir. Crit. Care Med. (1999) 1 6 0:S49–S52.
- BARNES PI Novel approaches and targets for treatmentof chronic obstructive pulmonary disease. Am. J Respir. Crit. Care Med. (1999) 1 6 0:S72–S79
- Trends in the US COPD therapeutics market. Drug &Market Development (1999) 258–261.
- KEATINGS VM, JATAKANON A, WORSDELL YM, BARNESPJ: Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J Respir. Crit. Care Med. (1997) 155:542-548. HURD S: Impact of COPD on lung health worldwide; Epidemiology and incidence. Chest (2000) 117:1S-4S. SULLIVAN SD, RAMSEY SD, LEE TA: Economic burden of COPD. Chest (2000) 117:5S-9S. NOGAMI H, AIZAWA H, MATSUMOTO K, et al.: Neutro-phil elastase inhibitor, ONO-5046 suppresses ozone-induced airway mucous hypersecretion in guinea pigs. Eur.J. Pharmacol (2000) 390:197–202.
- YAMAZAKI T, 00SHIMA H, USUI W, WATANABE T, YASUURA K: Protective effects of ONO-5046*Na, a specific neutrophil elastase inhibitor, on postperfu-sion lunginjury. Ann. Thorac. Surg. (1999) 68:2141–2146.
- MAUTAMAKI RD, KOBAYASHI DK, SENIOR RM, SHAPIROSD: Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science (1997) 277:2002–2004.
- CHURG A, WRIGHT J, GILKS B, et al.: Alp h a-1 -an titryp sinand the synthetic metalloprotease inhibitor RS113456 prevent dust induced connective tissue breakdown by suppressing the inflammatory response. Am. J Respir. Crit. Care Med. (2000) 161:A218.
- MASSARO G, MASSARO D: Retinoic acid treatmentabrogates elastase-induced pulmonary emphysema in rats. Nature Med. (1997) 3:675–677.
- MAO JT, ABERLE D, TASHKIN DP, GOLDIN J, ROTH MD: APhase II pilot study of all-trans retinoic acid for the treatment of human emphysema. Am. J. Respir. Crit. Care Med. (2000) 161 :A583.
- GIEMBYCZ MA: Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here Drugs (2000) 59:193–212.
- ••Comprehensive review of PDE4 inhibitors and respiratorydisease.
- FAWCETT L, BAXENDALE R, STACEY P, et al.: Molecularcloning and characterisation of a distinct human p h o sp h o dies ter ase gene family: PDE11 A. Proc. Nati Acad. Sci. USA (2000) 97:3702–3707.
- CONTI M, JIN SL: The molecular biology of cyclicnucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. (1999) 63:1–38.
- BARNETTE MS: Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog. Drug Res. (1999) 53:193–229.
- ••Comprehensive review of PDE4 inhibitors and respiratorydisease.
- KAMBAYASHI T, JACOB CO, ZHOU D, et al: Cyclic nucleotide phosphodiesterase Type IV participates in the regulation of IL-10 and in the subsequent in TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. J Immunol. (1995) 155:4909–4916.
- IZEBOUD CA, MONSHOUWER M, WITKAMP RF, VAN MIERT AS: Suppression of the acute inflammatory response of porcine alveolar -and liver macrophages. Vet Q (2000) 22:26–30.
- GRISWOLD DE, MARTIN LD, TORPHY TJ: ArifloTM (5B207499) is a potent inhibitor of leukotriene B4-induced mobilization of peripheral neutrophils in rabbits. Am. J. Respir. Crit. Care Med. (1999) 159:A33.
- LEE E, SMITH J, ROBERTSON T, et al: Salmeterol and inhibitors of phosphodiesterase 4 (PDE4) induce apoptosis in neutrophils from asthmatics. Am]. Respir. Crit. Care Med. (1999) 159:B34.
- HIDI R, TIMMERMANS S, LIU E, et al.: Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis. Eur. Respir. J. (2000) 15:342–349.
- COMPTON CH, GUBB J, CEDAR E, et al: The efficacy of Ariflo (SB 207499) a second-generation, oral PDE4 inhibitor, in patients with COPD. Am]. Respir. Crit. Care Med. (1999) 1 5 9:A806.
- COMPTON CH, GUBB J, CEDAR E, et al: Ariflo (SB 207499) a second-generation, oral PDE4 inhibitor, improves quality of life in patients with COPD. Am. J Respir. Crit. Care Med. (1999) 159:A806.
- SHIRE MG, MULLER GW: TNF-alpha inhibitors and rheumatoid arthritis. Exp. Opin. Ther. Patents (1998) 8:531–544.
- VAN HOGEZAND RA, VERSPAGET HW: The future role of anti-tumour necrosis factor-alpha products in the treatment of Crohn's disease. Drugs (1998) 56 (3):299–305.
- FELDMAN AM, COMBES A, WAGNER D, et al: The role of tumor necrosis factor in the pathophysiology of heart failure. J. Am. Coll. Cardiol. (2000) 35:537–544.
- DES WAL A, BOZKURT B, SETA Y et al.: Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation (1999) 99:3225–3226.
- LERNER A, KIM DH, LEER: The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. Leukemia and Lymphoma (2000) 3 7:39–51.
- NORMAN P: PDE4 inhibitors 1999. Exp. Opin. Ther. Patents (1999) 9:1101–1118.
- ••Very comprehensive review of PDE4 inhibitors, develop-ment and patents.
- TIMMER W, LECLERC V, BIRRAUX G, et al: Safety andefficacy of the new PDE4 inhibitor roflumilast administered to patients with exercise-induced asthma over 4 weeks. Am. J. Respir. Crit. Care Med. (2000) 161:A505.
- CELGENE CORPORATION PRESS RELEASE: Celgene Corporation files SelCID compound IND as a possible treatment for Crohn's Disease Phase II clinical trials to be launched at Cedars-Sinai Medical Center in Los Angeles. (November 24, 1998).
- Pharmaprojects Database. PJB Publications Ltd.
- LANDELLS LJ, et al.: Eur. Resp. J. (1998) 1 2 (Suppl. 28): Abstract P2393.
- GALE DD, LANDELLS LJ, SPINA D, et al.: Pharmacodynamic-pharmacokinetic (PD/PK) profile of the phosphodiesterase (PDE) 4 inhibitor, V11294A, in human volunteers. Am./ Respir. Crit. Care Med. (1999) 159:A611.
- JENSEN L, et al.: Mediators Inflamm. 4th World Cong.Inflamm. Paris, France (June 27–30 1999) 8 (Suppl. 1) Abstract P–11–10.
- PRUNIAUZ MP: Novel generation phosphodiesterase 4inhibitors for the treatment of asthma. PDE inhibitors: Drugs with an expanding range of therapeutic uses'. William Harvey Research Conferences. Nice, France (December 1–3 1999).
- FITZGERALD MF, BRIGGS BA, THOMPSON AM, EDWARDS DF, STURTON RG: The evaluation of a selective phosphodiesterase (PDE) 4 inhibitor BAY 19-8004, in guinea pig antigen challenge and ferret emesis models. Am. J. Respir. Crit. Care Med. (2000) 161:A201.
- STURTON RG, BUTT NM, PALFAI SP, et al: Molecular andcellular profile of the structurally novel phosphodies-terase (PDE) 4 inhibitor, BAY 19-8004. Am./ Respir. Crit. Care Med. (2000) 161 :A200.
- IWAHASHI Y, FURUYAMA T, TANO Y et al.: Differentialdistribution of mRNA encoding cAMP-specific phosphodiesterase isoforms in the rat brain. Mol. Brain. Res. (1996) 38:14–24.
- HERSPERGER R, BRAY-FRENCH K, MAZZONI L, MULLER T:Palladium-catalysed cross-coupling reactions for the synthesis of 6,8-disubstituted 1,7-naphthridines: A novel class of potent and selective phosphodiesterase Type 4D inhibitors. J. Med. Chem. (2000) 43:675–682.
- MCPHEE I, YARWOOOD SJ, SCOTLAND G, et al.: Associa-tion with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDF4A4B. Consequences for rolipram inhibition./ Biol. Chem. (1999) 274:11796–11810.
- BAROJA ML, CIESLINSKI LB, TORPHY TJ, WANGE RL, MADRENAS J: Specific CD3 epsilon association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation. J. Immunol. (1999) 162:2016–2023.
Bibliography
- http://www.who.org WORLD HEALTH ORGANIZATION: 1999 World Health Report.
- http://www.nhlbi.nih.gov NATIONAL HEART LUNG 8z BLOOD INSTITUTE: Morbidity and mortality: 2000 chart book on cardiovascular, lung and blood diseases. May 2000.
- http://www.statcan.ca STATISTICS CANADA, HEALTH STATISTICS DIVISION: Selected leading causes of death by sex, Canada,1995.
- http://www.statistics.gov.uk/statbase OFFICE OF NATIONAL STATISTICS: Deaths: selected causes (International Classification) and sex, 1971 onwards (England and Wales) Health Statistics Quarterly 06.
- http://www.uspo.gov UNITED STATES PATENT OFFICE WEBSITE
- http://www.prous.com PROUS INFORMATION SERVICE